These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
111 related articles for article (PubMed ID: 24582410)
1. [Intravenous ferric carboxymaltose for the treatment of anemia in chronic renal disease]. Merino JL; Bueno B; Campos MA; Amézquita Y Rev Clin Esp (Barc); 2014; 214(5):282-3. PubMed ID: 24582410 [No Abstract] [Full Text] [Related]
2. Anaemia tolerance: bridging with intravenous ferric carboxymaltose in a patient with acute post-haemorrhagic anaemia. Hönemann CW; Doll D; Kampmeier T; Ertmer C; Hagemann O; Hahnenkamp K Br J Anaesth; 2012 Jan; 108(1):167-8. PubMed ID: 22157459 [No Abstract] [Full Text] [Related]
3. Switching patients with non-dialysis chronic kidney disease from oral iron to intravenous ferric carboxymaltose: effects on erythropoiesis-stimulating agent requirements, costs, hemoglobin and iron status. Toblli JE; Di Gennaro F PLoS One; 2015; 10(4):e0125528. PubMed ID: 25928811 [TBL] [Abstract][Full Text] [Related]
4. The efficacy of a single dose of intravenous ferric carboxymaltose (Ferinject) on anaemia in a pre-dialysis population of chronic kidney disease patients. Tagboto S; Cropper L; Turner J; Pugh-Clarke K J Ren Care; 2009 Mar; 35(1):18-23. PubMed ID: 19200274 [TBL] [Abstract][Full Text] [Related]
5. Oxidative stress markers in predicting response to treatment with ferric carboxymaltose in nondialysis chronic kidney disease patients. Prats M; Font R; García C; Muñoz-Cortés M; Cabré C; Jariod M; Romeu M; Giralt M; Martinez-Vea A Clin Nephrol; 2014 Jun; 81(6):419-26. PubMed ID: 24691014 [TBL] [Abstract][Full Text] [Related]
6. Intravenous ferric carboxymaltose for iron deficiency anaemia in pregnancy. Nwagha UI; Nwagha TU Lancet Glob Health; 2024 Oct; 12(10):e1567-e1568. PubMed ID: 39304228 [No Abstract] [Full Text] [Related]
7. Intravenous iron treatment in pregnancy: comparison of high-dose ferric carboxymaltose vs. iron sucrose. Christoph P; Schuller C; Studer H; Irion O; De Tejada BM; Surbek D J Perinat Med; 2012 May; 40(5):469-74. PubMed ID: 22945271 [TBL] [Abstract][Full Text] [Related]
8. Intravenous ferric carboxymaltose versus standard medical care in the treatment of iron deficiency anemia in patients with chronic kidney disease: a randomized, active-controlled, multi-center study. Charytan C; Bernardo MV; Koch TA; Butcher A; Morris D; Bregman DB Nephrol Dial Transplant; 2013 Apr; 28(4):953-64. PubMed ID: 23222534 [TBL] [Abstract][Full Text] [Related]
9. Intravenous Iron Carboxymaltose as a Potential Therapeutic in Anemia of Inflammation. Lofruthe N; Gallitz I; Traeger L; Bäumer N; Schulze I; Kuhlmann T; Müller-Tidow C; Steinbicker AU PLoS One; 2016; 11(7):e0158599. PubMed ID: 27404499 [TBL] [Abstract][Full Text] [Related]
10. Intravenous ferric carboxymaltose compared with oral iron in the treatment of postpartum anemia: a randomized controlled trial. Van Wyck DB; Martens MG; Seid MH; Baker JB; Mangione A Obstet Gynecol; 2007 Aug; 110(2 Pt 1):267-78. PubMed ID: 17666600 [TBL] [Abstract][Full Text] [Related]
11. "Camel humps"-shaped red blood cell histogram in a woman with extreme anemia treated with intravenous iron. Beverina I; Scalvini R; Brando B Transfusion; 2021 Feb; 61(2):348-349. PubMed ID: 33111350 [No Abstract] [Full Text] [Related]
12. Iron status and analysis of efficacy and safety of ferric carboxymaltose treatment in patients with inflammatory bowel disease. Beigel F; Löhr B; Laubender RP; Tillack C; Schnitzler F; Breiteneicher S; Weidinger M; Göke B; Seiderer J; Ochsenkühn T; Brand S Digestion; 2012; 85(1):47-54. PubMed ID: 22179489 [TBL] [Abstract][Full Text] [Related]
13. Use of intravenous iron supplementation in chronic kidney disease: an update. Macdougall IC; Geisser P Iran J Kidney Dis; 2013 Jan; 7(1):9-22. PubMed ID: 23314137 [TBL] [Abstract][Full Text] [Related]
14. Intravenous Iron Use in the Care of Patients with Kidney Disease. Macdougall IC Clin J Am Soc Nephrol; 2019 Oct; 14(10):1528-1530. PubMed ID: 31175103 [No Abstract] [Full Text] [Related]
15. Anemia and iron deficiency in inflammatory bowel disease: an open, prospective, observational study on diagnosis, treatment with ferric carboxymaltose and quality of life. Befrits R; Wikman O; Blomquist L; Hjortswang H; Hammarlund P; Bajor A; Klintman D; Blom H Scand J Gastroenterol; 2013 Sep; 48(9):1027-32. PubMed ID: 23889159 [TBL] [Abstract][Full Text] [Related]
16. Progress in intravenous iron treatment. Marx JJ Arzneimittelforschung; 2010; 60(6a):341-4. PubMed ID: 20648925 [No Abstract] [Full Text] [Related]
17. Evaluation of cost savings with ferric carboxymaltose in anemia treatment through its impact on erythropoiesis-stimulating agents and blood transfusion: French healthcare payer perspective. Luporsi E; Mahi L; Morre C; Wernli J; de Pouvourville G; Bugat R J Med Econ; 2012; 15(2):225-32. PubMed ID: 22077267 [TBL] [Abstract][Full Text] [Related]
18. Iron supplementation in a case of severe iron deficiency anaemia. Füllenbach C; Triphaus C; Glaser P; Ziebart A; Zacharowski K; Meybohm P; Choorapoikayil S Br J Anaesth; 2018 Aug; 121(2):502-504. PubMed ID: 30032895 [No Abstract] [Full Text] [Related]
19. A multicentre comparative study on the efficacy of intravenous ferric carboxymaltose and iron sucrose for correcting preoperative anaemia in patients undergoing major elective surgery. Bisbe E; García-Erce JA; Díez-Lobo AI; Muñoz M; Br J Anaesth; 2011 Sep; 107(3):477-8. PubMed ID: 21841061 [No Abstract] [Full Text] [Related]
20. Intravenous ferric carboxymaltose compared with oral iron in the treatment of postpartum anemia: a randomized controlled trial. Urato AC Obstet Gynecol; 2008 Sep; 112(3):703. PubMed ID: 18757678 [No Abstract] [Full Text] [Related] [Next] [New Search]